Search the Community
Showing results for tags 'lutetium trials'.
Found 2 results
Not to be missed February 20th 2018 Associate Professor Michael Hofman is coming to Prostate Heidelberg in Melbourne to address members on ”Diagnostic & Treatment Paradigms using PET Scans” We have some seats to spare for this Meeting and we extend an invitation to members of our Advanced Group who might be in the Melbourne area on this day to join us for this special event. It’s free - morning tea will be provided but please book in advance by phoning Barry 0400 662 114 or emailing email@example.com Associate Professor Hofman is a nuclear medicine physician at the Centre for Molecular Imaging and Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, this is Australia's only public hospital dedicated to cancer treatment, research and education. He is currently involved in the multi-centre randomized clinical trial of Gallium 68 PSMA PET Scans and the trials of the game changing Lutetium 177 PSMA therapy which is about to commence Australia wide. These trials are cutting edge imaging / treatments for Advanced Metastatic Prostate Cancer. Associate Professor Hofman is one of Australia’s — and possibly one of the World’s — leading physicians specializing in Pet & Radio Tracer Scans & Neuroendocrine Tumors & Theranostic treatments like Lutetium177 . Where : - The Uniting Church Meeting Room, Sneddon Street, Ivanhoe - 10.00am sharp There is a car park adjoining the rooms. Parking is free but it can get busy at times. If you can make it don’t miss this golden opportunity to hear Associate Professor Michael Hoffman’s address on these ground - breaking treatments Presented by PROSTATE HEIDELBERG - CANCER SUPPORT GROUP We are Proudly Affiliated with the Prostate Cancer Foundation of Australia and the Cancer Council of Victoria PO Box 241 Ivanhoe Vic 3079 Email :- firstname.lastname@example.org Web Site ttp://www.prostateheidelberg.info/
The long awaited trial results of the phase II trials at Peter Mac were presented at the ESMO European Society Medical Oncologists over the weekend,8th & 9th of September 2017. Near on 23000 participants from 131 Countries are in attendance at the conference. Dr. Hofman and colleagues from Melbourne, Australia presented results from their phase II Lutetium-177 PSMA trial for the treatment of metastatic castrate-resistant prostate cancer. This treatment provides an opportunity for new therapeutic technology to be used to improve survival. Another interesting article presented at the same session was Targeted Alpha Therapy(TAT) by Professor Johann de Bono from the UK He discussed the future of targeted alpha therapy. Dr. de Bono shared a comprehensive slide delineating the timeline of alpha-emitting radionuclide therapy in oncology, specifically highlighting radium-223 approval in mCRPC in 2013 and the first patient being treated with Thorium-227 in 2016. The study conclusion: In conclusion, this phase II trial demonstrates that 177Lu-PSMA treatment for patients with mCRPC who have failed standard therapy provides encouraging response rates with acceptable toxicity, in addition to improved QoL and pain reduction. Based on this trial, we eagerly await the results of larger studies with long-term follow-up. This information is on the URO Today site.. Lutetium Trial Results September 2017 ESMO (This is on UroToday. It is only available to UroToday members, so you will have to join up to see it. Joining is free.) countries are attending the 2017 Congress, being held 8 to 12 September in Madrid 23,000 participants from 131 countries are attending th2017 Congress, being held 8 to 12 September in Madrid